Table 2.

Clinical efficacy of MMX mesalamine (MES) in induction (8 weeks) of remission in patients with mild to moderate ulcerative colitis

Study	N	Doses	Clinical and endoscopic remission (%) (OR, 95% CI)	Failure rates (%)
Kamm et al39	84	MMX mesalamine 2.4 g daily	40.5** (2.40; 1.23–4.69)	21.4***
	85	MMX mesalamine 4.8 g daily	41.2** (2.47; 1.15–5.30)	20.0***
	86	Asacola 800 mg three times daily	32.6 (1.70; 0.86–3.36)	27.9**
	86	Placebo	22.1	47.7
Lichtenstein et al56	88	MMX mesalamine 1.2 g twice daily	34.1*** (3.48; 1.44–8.41)	28.4***
	85	MES 4.8 g daily	29.2** (2.78; 1.27–6.06)	24.7***
	89	Placebo	12.9	54.1
Kamm et al58,b	197	MMX mesalamine 2.4 g twice daily (No response to MMX mesalamine previously)	59.5	_
	107	MMX mesalamine 2.4 g twice daily (Placebo previously)	57	_

Notes:

^*P < 0.05;

^**P < 0.01;

^***P < 0.001 vs placebo.

^aIncluded as an internal reference arm; no comparative statistical analyses with the mesalamine treatment arms were reported;

^bpatients who did not achieve the primary endpoint of clinical and endoscopic remission in the 8-week Phase III trials35,51 were eligible for enrolment in the noncomparative extension study (4.8 g MMX mesalamine for 8 weeks).54

Abbreviation: OR, odds ratio.